Vertex Pharmaceuticals (VRTX) is facing technical challenges, with its stock forming a Death Cross and down 15% in 6 months.

Vertex is paying Orna $65 million upfront, in part via convertible note, according to a Jan. 7 release. Orna—which acquired ...

The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine for sickle cell and beta thalassemia.

Vertex VERX shares have skyrocketed 107.3% in the past 12 months, outperforming the Zacks Computer Technology sector, Zacks ...

The deal is set to help Vertex’s development of next-generation gene editing therapies for sickle cell disease and ...

Orna Therapeutics, through its subsidiary ReNAgade Therapeutics, announced a three-year strategic research collaboration with Vertex ...

Bernstein analyst William Pickering maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target of ...

The FDA will decide later this month whether to approve a novel drug for acute pain that could offer a nonaddictive ...

Here are five stocks added to the Zacks Rank #1 (Strong Buy) List today: Artivion, Inc. AORT: This medical device and tissue ...

Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 7: NextNav Inc. NN: This positioning, navigation, and timing (PNT) solutions provider ...

New research by Security Intelligence has revealed security risks in MLOps platforms including Azure ML, BigML and Google ...

Like its competitors, Google continues to experiment with low- and no-code tools that harness agentic AI for business ...